<DOC>
	<DOCNO>NCT02193893</DOCNO>
	<brief_summary>The purpose study test safety effectiveness autologous bone marrow-derived stem/progenitor cell infusion subject diagnose amyotrophic lateral sclerosis .</brief_summary>
	<brief_title>Biological Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) universally fatal neurodegenerative condition cause weakness lead paralysis death . Life expectancy le 5 year . The cause generally unknown effective treatment . Patients ALS typically exhibit progressive paralysis due continue loss motoneuron . Intraspinal injection bone marrow mononuclear cell able ameliorate course ALS murine model . The purpose prospective , nonrandomized , open label , pilot study conduct investigation safety efficacy infusion autologous bone marrow-isolated stem/progenitor cell different select phenotype subject diagnosed ALS . Especially , clinical trial designate test therapeutic ( pro-regenerative neuro-protective ) function different stem/progenitor cell population able secrete bioactive neurotrophic factor . All patient enrol documented history ALS disease prior study enrollment . Patients diagnose early stage ALS duration disease le 6 month patient diagnose advanced stage ALS disease duration 6-12 month recruit allocate base disease severity two treatment group : Group I - patient early ALS disease stage Group II - patient advanced ALS disease . Next , autologous bone marrow-isolated stem/progenitor cell administration cerebrospinal fluid site spinal cord perform . Finally , treatment safety , adverse event exploratory parameter , include electromyographic ( EMG ) study , force vital capacity ( FVC ) , functional rating scale ( FRS ) maximum voluntary isometric contraction-arm ( MVIC-arm ) evaluation , establish ALS progression rate record throughout duration post-treatment follow period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<criteria>diagnosis ALS disease cell transplantation ( diagnose establish follow El Escorial criterion definite ALS ) good understand protocol willingness consent patient mentally intact psychologically stable sign informed consent Concomitant systemic disease disease : inflammation ( high protein lymphocytosis CSF ) , active infection . diabetes , cardiovascular disorder , cancer , autoimmune disease renal failure , impaired hepatic function . subject respiratory dependent . subject unwilling unable comply requirement protocol . patient treat previously cellular therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>cell-based therapy</keyword>
	<keyword>autologous bone marrow-derived stem/progenitor cell</keyword>
	<keyword>stem cell infusion , stem cell transplantation</keyword>
	<keyword>biological therapy neurotrophic factor</keyword>
	<keyword>bioactive neurotrophic factor</keyword>
</DOC>